相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
Erik Kupperman et al.
CANCER RESEARCH (2010)
The persisting challenge of selective and specific proteasome inhibition
Michael Groll et al.
JOURNAL OF PEPTIDE SCIENCE (2009)
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Teresa A. Soucy et al.
NATURE (2009)
A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis
Tony Muchamuel et al.
NATURE MEDICINE (2009)
Proteasome inhibitors in cancer therapy: Lessons from the first decade
Robert Z. Orlowski et al.
CLINICAL CANCER RESEARCH (2008)
Distinct Specificities of Mycobacterium tuberculosis and Mammalian Proteasomes for N-Acetyl Tripeptide Substrates
Gang Lin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib
Roberto Piva et al.
BLOOD (2008)
Extended follow-up of a phase 3 trial in relapsed multiple myeloma:: final time-to-event results of the APEX trial
Paul G. Richardson et al.
BLOOD (2007)
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelorna
Deborah J. Kuhn et al.
BLOOD (2007)
Linear TMC-95-based proteasome inhibitors
Nicolas Basse et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy
A. L. Goldberg
BIOCHEMICAL SOCIETY TRANSACTIONS (2007)
20S proteasome and its inhibitors: Crystallographic knowledge for drug development
Ljudmila Borissenko et al.
CHEMICAL REVIEWS (2007)
Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib
Mark J. Williamson et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
Richard I. Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
TMC-95-based inhibitor design provides evidence for the catalytic versatility of the proteasome
Michael Groll et al.
CHEMISTRY & BIOLOGY (2006)
Optimization of subsite binding to the β5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles:: Syntheses and cellular properties of potent, selective proteasome inhibitors
Robert M. Rydzewski et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of β-lactone ring opening and a mechanism for irreversible binding
M Groll et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2006)
Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome
M Groll et al.
STRUCTURE (2006)
Peptide and peptide-like modulators of 20S proteasome enzymatic activity in cancer cells
C García-Echeverría
INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS (2006)
The integration of macromolecular diffraction data
AGW Leslie
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2006)
Scaling and assessment of data quality
P Evans
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2006)
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
D Chauhan et al.
CANCER CELL (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Proteasomes and their kin: Proteases in the machine age
CM Pickart et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Entry into a new class of potent proteasome inhibitors having high antiproliferative activity by structure-based design
P Furet et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
PRODRG:: a tool for high-throughput crystallography of protein-ligand complexes
AW Schüttelkopf et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2004)
Coot:: model-building tools for molecular graphics
P Emsley et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2004)
A graphical user interface to the CCP4 program suite
E Potterton et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2003)
Imaging 26S proteasome activity and inhibition in living mice
GD Luker et al.
NATURE MEDICINE (2003)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Multiple associated proteins regulate proteasome structure and function
DS Leggett et al.
MOLECULAR CELL (2002)
The structure of the mammalian 20S proteasome at 2.75 Å resolution
M Unno et al.
STRUCTURE (2002)
Proteasome inhibitors: from research tools to drug candidates
AF Kisselev et al.
CHEMISTRY & BIOLOGY (2001)
A new structural class of selective and non-covalent inhibitors of the chymotrypsin-like activity of the 20S proteasome
C Garcia-Echeverría et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2001)
Antigen processing by the proteasome
PM Kloetzel
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
A gated channel into the proteasome core particle
M Groll et al.
NATURE STRUCTURAL BIOLOGY (2000)
Crystal structure of epoxomicin:20S proteasome reveals a molecular basis for selectivity of α′,β′-epoxyketone proteasome inhibitors
M Groll et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2000)
分享论文
